Status:

COMPLETED

Evaluation of Software Enhancements to the Respironics BiPAP Auto Servo Ventilation (AutoSV) Device

Lead Sponsor:

Philips Respironics

Conditions:

Sleep Disordered Breathing

Sleep Apnea, Central

Eligibility:

All Genders

21-80 years

Phase:

NA

Brief Summary

This study is being undertaken to collect data from Respironics Inc's BiPAP Auto Servo Ventilation 3 (autoSV3) and compare with data from Respironics, Inc's BiPAP autoSV2, to confirm that the algorith...

Detailed Description

This study was conducted to evaluate the therapeutic performance of a new auto Servo Ventilation device (Philips Respironics autoSV Advanced) for the treatment of complex central sleep apnea (CompSA)....

Eligibility Criteria

Inclusion

  • Pre-Study
  • Age 21-80
  • Ability to provide consent
  • Documentation of medical stability by investigator
  • Enrollment
  • • Participants who, during the ambulatory polysomnography (PSG) study (Stardust), or in lab Diagnostic PSG demonstrated an Apnea Hypopnea Index (AHI) ≥10 or Central Apnea Index (CAI) ≥5
  • or
  • • Participants who previously demonstrated Central sleep Apnea (CSA), with a CAI≥5 on Continuous Positive Airway Pressure (CPAP) titration.

Exclusion

  • • Participants who are acutely ill, medically complicated or who are medically unstable.
  • Pregnancy (will confirm absence of pregnancy with a urine or serum pregnancy test in women of child bearing potential).
  • Participants in whom PAP therapy is otherwise medically contraindicated.
  • Participants who are unwilling to wear CPAP
  • Participants who are currently prescribed nocturnal oxygen use and are unable to forego oxygen during study nights.
  • Participants with previously diagnosed respiratory failure or respiratory insufficiency and who are known to have chronically elevated arterial carbon dioxide levels while awake (PaCO2 ≥ 45mmHg).
  • Participants who have had surgery of the upper airway, nose, sinus, or middle ear within the previous 90 days.
  • Participants with untreated, non- Obstructive Sleep Apnea (OSA)/CSA sleep disorders, including but not limited to; insomnia, periodic limb movement syndrome, or restless legs syndrome (PLM Arousal Index \> 15).
  • Participants who are unwilling to participate in the study.

Key Trial Info

Start Date :

August 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2009

Estimated Enrollment :

44 Patients enrolled

Trial Details

Trial ID

NCT00720213

Start Date

August 1 2008

End Date

July 1 2009

Last Update

January 29 2019

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

University of Arizona

Tucson, Arizona, United States, 85724

2

Arkansas Center for Sleep Medicine

Little Rock, Arkansas, United States, 72205

3

Mark G. Goetting

Portage, Michigan, United States, 49024

4

Ohio State University

Columbus, Ohio, United States, 43210